Media, investors, advocacy organizations and others, please contact us here.

Publications FSGS

Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety

View
Publications FSGS

Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study

View
Publications FSGS

Kidney Failure Attributed to Focal Segmental Glomerulosclerosis: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden

View
Medical Information FSGS

FILSPARI (sparsentan) – 2-Year Results from the Phase 3 DUPLEX Study Published in the NEJM

Learn more
Publications FSGS

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

View
Posters FSGS

Understanding the Impact of Immunoglobulin ANephropathy (IgAN) and Focal Segmental Glomerulosclerosis (FSGS) on Patients and Care-Partners Study(HONUS): Updated Results for IgAN in the United States (US)

Learn More
Publications FSGS

Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial

View
Medical Information FSGS

EPPIK (Phase 2 Study): Treatment in Pediatric Patients With Proteinuric Glomerular Diseases

Learn more
Medical Information FSGS

PROTECT (Phase 3 Study): Study Design & Results

Learn more
Medical Information FSGS

Phase 2 DUET Study Published in the Journal of the American Society of Nephrology

Learn more
Medical Information FSGS

FILSPARI (sparsentan): Continued Use

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Effect on Estimated Glomerular Filtration Rate (eGFR)

Learn more
Medical Information FSGS

FILSPARI (sparsentan): Sparsentan and the Treatment Landscape for IgA Nephropathy

Learn more